Eli Lilly & Co. is asking people who took copies of its blockbuster weight loss drug to give the company access to their medical records for safety reasons, a move that comes as it builds a case ...

Gift 5 articles to anyone you choose each month when you subscribe. Times are good at Eli Lilly. Wall Street’s insatiable appetite for weight-loss drug stocks looks set to turn the company into ...

Eli Lilly and Company (NYSE: LLY) announced data demonstrating more patients with moderately to severely active Crohn's disease treated with mirikizumab achieved histologic response at Week 52 ...

WIRED is where tomorrow is realized. It is the essential source of information and ideas that make sense of a world in constant transformation. The WIRED conversation illuminates how technology is ...

Machine-learning drug development company Insitro has inked three agreements with Eli Lilly for new medicines for metabolic diseases. But the deal is a little different compared to many recent ...

Drugmaker Eli Lilly said it will spend $4.5 billion to build a new manufacturing research hub in Indiana, where it will develop new methods of producing complicated types of medicines. The Lilly ...

Eli Lilly has become a household name thanks to breakthrough diabetes and obesity care medicines. The stock has trounced the broader market over the past year, and shares have become a bit pricey.

Sept 18 (Reuters) - Drugmaker Eli Lilly (LLY.N), opens new tab on Wednesday urged a federal appeals court to overturn a $183 million judgment against it in a case accusing it of defrauding ...

Eli Lilly’s two weight loss drugs have become blockbusters, bringing in more than $1 billion in annual revenue. Demand is growing in this market, but so is competition. These players ...

Oct 7 (Reuters) - A drug compounding industry group on Monday sued the U.S. Food and Drug Administration over its decision to take Eli Lilly’s (LLY.N), opens new tab blockbuster weight loss and ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Stelara is one of the most successful Crohn’s therapies, generating $10.8bn last year, Lilly hopes to introduce Omvoh as its competitor. Eli Lilly (LLY) has partnered with the government of the ...